Skip to main content
. Author manuscript; available in PMC: 2022 Sep 1.
Published in final edited form as: Neuropharmacology. 2021 Jun 18;195:108673. doi: 10.1016/j.neuropharm.2021.108673

Figure 7. Comp5 has no impact on breathing and heart rates.

Figure 7.

Breathing and heart rates were measured in conscious/freely moving female C57Bl/6 mice using the MouseOx Plus apparatus. Data represent four mice with respiratory and heart rate data combined and binned in 30-minute increments. The lower and upper error bars represent the 25th and 75th percentiles, respectively. Statistics are based on non-paired, two-sided t-tests. For breathing rates, T = −1.11, 0.16, 7.68, and 0.75, for Vehicle, 10 mg/kg MOR, 30 mg/kg MOR, and 40 mg/kg Comp5, respectively. For 2 mg/kg MOR + 40 mg/kg Comp5, T=−1.01 and −0.97 for comparison of the 30-min pre-dose with the 30 min after the first dose and with the 30 min after the second dose; *** p < 0.001 , ** p < 0.01, n.s. p>0.05; number of observations=12-38 per group. For heart rates, T=0.21, 5.76, 8.15, 3.14, for Vehicle, 10 mg/kg MOR, 30 mg/kg MOR, and 40 mg/kg Comp5, respectively. For 2 mg/kg MOR + 40 mg/kg Comp5, T=3.81 and 8.62 for comparison of the 30-min pre-dose with the 30 min after the first dose and with the 30 min after the second dose; *** p < 0.001 , ** p< 0.01, n.s. p >0.05; number of observations=10-36 per group.